



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/821,240	04/08/2004	Nisar Ahmed Khan	2183.03-6384US	9732
24247 TRASK BRITT P.O. BOX 2550 SALT LAKE CITY, UT 84110	7590 02/28/2008			
EXAMINER				
SKOWRONEK, KARL HEINZ R				
ART UNIT		PAPER NUMBER		
1631				
NOTIFICATION DATE		DELIVERY MODE		
02/28/2008		ELECTRONIC		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPTOMail@traskbritt.com

### Office Action Summary

**Application No.**

10/821,240

**Applicant(s)**

KHAN ET AL.

**Examiner**

KARLHEINZ R. SKOWRONEK

**Art Unit**

1631

**Period for Reply** -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 31 October 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 27 and 47-52 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 27 and 47-52 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-8508)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 31 October 2007 has been entered.

### ***Claim Status***

Claims 27 and 47-52 are pending.

Claims 1-26 and 28-46 are cancelled.

Claims 47-52 are new.

Claims 27 and 47-52 are being examined.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of

the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 27 and 47-52 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ivanov et al. (IDS filed 4/12/2006, ref No. 1), in view of Werner et al. (Experientia Vol. 42, p. 521-531, 1986), in view of Lam et al. (US PAT 5,650,489), in view of Houghten et al. (DDT, Vol. 5, No. 7, p. 276-285, July 2000) and in view of Lin et al.

The claims are directed to a method of producing a pharmaceutical comprising identification of a protein that is cleaved into fragments consisting of 3-9 amino acids that have an activity; analyzing the fragment for biological activity; entering data from biological activity analysis of the peptide into a database; determining the identity of a peptide that modulates septic shock, release of inflammation mediators, NF-kappa B regulation, regulation of sepsis, nitrate production, nitric oxide production, glucose

tolerance, or combinations, conducting therapeutic profiling for efficacy and toxicity; and formulating a pharmaceutical preparation. In an embodiment, the peptide activity is different from the active of the protein from which it is derived. In an embodiment, the peptides consist of trimers and tetramers.

Ivanov et al. shows the identification of hemoglobin as a source of biologically active peptides (p. 172, col. 2). Ivanov et al. shows that peptides derived from hemoglobin are 3-9 amino acids in length (figure 4). Ivanov et al. shows that the biological activity analysis is entered in to a database which is shown in the forma of tables (table VII and VIII). Ivanov et al. suggest that the endogenous fragmentation of hemoglobin and consequent formation of biologically active peptides is not an isolated phenomenon; rather it is shared among other proteins such as cytochrome C oxidase, immunoglobulins, albumin, fibrinogen, and others (p. 186, col. 1).

Alternatively, Werner et al. shows immuno-modulating peptides can be derived from the proteolytic degradation of proteins. Werner et al. shows that the tetrapeptide tuftsin is derived from the Fc region of Leukokinin through its proteolytic degradation with tuftsin-endopeptidase and leukokininase (p. 526, col. 2). In an embodiment, Werner et al. shows that the activity of Tuftsin is different from the activity of antibody from which it is derived (p. 526, col. 2). Werner et al. shows fibronectin is degraded by plasminogen to for fibrinogen degradation products having immuno-modulatory activity (p. 527, col. 1). Werner et al. shows that proteolytic digestion of human casein produced peptide fragments that have immuno-modulatory activity (p. 528, col. 1). Werner et al. also shows that tripeptides were also identified with immuno-modulatory activity (p. 528,

col. 1). Werner et al. shows that the tripeptide TKP which is a proteolytic cleavage product of tuftsin, modulates the release of the inflammation mediator IL-1 (p. 526, col. 2). Werner et al. suggest that immunomodulatory peptides may be useful as drugs (p. 529, col. 2).

Ivanov et al. and Werner et al. do not show conducting therapeutic profiling for toxicity and efficacy or the formulation of a pharmaceutical preparation.

Lin et al. teach a method of producing a pharmaceutical in which the identity of a compound is determined which modulates glucose tolerance. It is generally accepted in the art that individuals that have diabetes have an altered tolerance to glucose levels and therefore a compound as disclosed in Lin et al. to modulate or provide a therapeutic benefit for diabetes would modulate glucose tolerance. In Lin et al, compounds are identified that modulate the signaling pathways that include ephrin-PDZ interactions (p. 2, [0020]) that provide a therapeutic benefit to diseases of the immune system (p. 3, [0033]). One disclosed assay system is a search of members of a random peptide library reading on searching a peptide database (p. 15, [0158]). The identified compounds are profiled therapeutically for efficacy toxicity and in animals (p. 2, [0021]). Suitable compounds are then formulated into a pharmaceutical preparation (p. 2, [0022]). Lin shows that peptides have therapeutic benefits and increased stability and reduced host immune recognition ([0094]).

Lam et al. shows a method of producing libraries of biopolymers of defined size and composition. Lam et al. shows that the method provides a powerful and faster way to identify useful biopolymers from a library (abstract). Lam et al. defines peptide to refer

to a compound of 2 or more amino acids linked by peptide bonds (col. 7, line 58-62).

Lam et al. shows that the synthesis of the library is performed in iterative manner allowing production of n-mers, peptides of any number of amino acids in length (col. 10, line 33-31). Lam shows the synthesis of a tetrapeptide library (col. 33, line 50-65). Lam et al. shows the peptide libraries can identify peptides that have immuno-modulatory activity (col. 31, line 35 to 32, line 67).

Houghten et al. shows searching tripeptide and tetrapeptide libraries (p. 279, col. 2). Houghten et al. shows searching using mixed compounds is beneficial in terms of time and cost savings as well as providing a way to rapidly screen compounds to identify highly active individual compounds (p. 279, col. 2).

It would have been obvious to one of skill in the art to modify the identification of proteins that are degraded to for biologically active fragments of 3-9 amino acids in length and specifically 3-4 amino acids in length of Werner et al. or Ivanov et al. with the method of producing pharmaceutical of Lin et al. because Lin et al. shows peptides have therapeutic benefits and increased stability and reduced host immune recognition. It would have been further obvious to one of skill in the art to modify the identification of proteins that are degraded to biologically active fragments of 3-9 amino acids in length and specifically 3-4 amino acids in length of Werner et al. and Ivanov et al. with the method of producing pharmaceutical of Lin et al. because Werner et al. shows immuno-modulatory peptides may be useful as drugs and Ivanov et al. shows the endogenous fragmentation of hemoglobin and consequent formation of biologically active peptides is not an isolated phenomenon; rather it is shared among other proteins such as

Art Unit: 1631

cytochrome C oxidase, immunoglobulins, albumin, fibrinogen, and others. It would have been further obvious to one of skill in the art to modify the method of producing a pharmaceutical that is based on peptide fragments of a protein's proteolytic degradation with the library of Lam et al. because Lam et al. shows it is a powerful and faster way to identify useful biopolymers from a library. It would have been further obvious to one of skill in the art to modify the method of producing a pharmaceutical that is based on peptide fragments of a protein's proteolytic degradation with tripeptide and tetrapeptide libraries of Houghten et al. because Houghten et al. shows searching using mixed compounds is beneficial in terms of time and cost savings as well as providing a way to rapidly screen compounds to identify highly active individual compounds.

### ***Response to Arguments***

Applicant's argument, see remarks p. 5-7, filed 31 October 2007, with respect to the rejection of claim 27 and 47 as unpatentable over Lin et al. in view of Hammond et al. under 35 USC 103(a) have been fully considered and are persuasive. The rejection of claims 27 and 47 has been withdrawn.

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to KARLHEINZ R. SKOWRONEK whose telephone



Art Unit: 1631

number is (571)272-9047. The examiner can normally be reached on Mon-Fri 8:00am-5:00pm (EST).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marjorie A. Moran can be reached on (571) 272-0720. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

29 February 2008

/K. R. S./  
Examiner, Art Unit 1631

/John S. Brusca/  
Primary Examiner, Art Unit 1631